From Molecule to Market: Where Medical Affairs Creates Biotech Value

This article concludes MA Pulse's three-part series exploring how Medical Affairs creates value across the development lifecycle, from translating insight into strategic influence to building the capabilities and organizational readiness that drive long-term success.

It draws from a recent episode of Medical Affairs Unscripted, where Peg Crowley-Nowick, PhD, MBA, Senior Advisor, Lumanity, speaks with Nicholas Sen, PhD, Senior Vice President and Practice Lead, Medical Affairs Consulting at Lumanity. Their conversation is further informed by Sen’s newly released white paper, The Medical Affairs Blueprint for Biotech: A Strategy to De-Risk Development, Accelerate Approval, and Secure Patient Access.

Together, the episode and white paper make a compelling case for Medical Affairs as a strategic engine of biotech value, helping shape the decisions that determine whether an asset succeeds long before launch.